VIVUS Press Releases

Date Title Links
Toggle Summary VIVUS Reports Third Quarter 2019 Financial Results
Company to host conference call today at 4:30pm ET CAMPBELL, Calif. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- VIVUS , Inc. (NASDAQ: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with
View HTML
Toggle Summary VIVUS Announces Departures of Eric W. Roberts and Allan L. Shaw from Board of Directors
CAMPBELL, Calif. , Oct. 28, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, announced today that Eric W. Roberts and Allan L. Shaw have resigned from its Board of Directors and all of its committees in order to increase their focus on other personal
View HTML
Toggle Summary VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 5, 2019
CAMPBELL, Calif. , Oct. 22, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the third quarter of 2019 after the market close on Tuesday, November 5, 2019 . The company will host a conference call beginning
View HTML
Toggle Summary VIVUS to Highlight Integrated Approach to More Effective Weight Management in Panel Discussion at the Cleveland Clinic 2019 Medical Innovation Summit
CAMPBELL, Calif. , Oct. 21, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, announced today that John Amos , Chief Executive Officer, will participate in a panel discussion at the Cleveland Clinic 2019 Medical Innovation Summit, which is taking
View HTML
Toggle Summary VIVUS Announces Acceptance of Qsymia Decentralized Marketing Authorization Application in Europe
CAMPBELL, Calif. , Oct. 07, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, announced today that European regulatory agencies in Sweden , Denmark , Finland , Iceland , Norway , and Poland (the “Concerned Member States”) have accepted the Marketing
View HTML
Toggle Summary VIVUS Initiates Pay Down of Secured Debt and Announces Management Changes
-Reduction of $48.6 million of Secured Debt will result in total interest savings of $10.5 million - -Organizational change streamlines commercial operations- CAMPBELL, Calif. , Oct. 03, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today
View HTML
Toggle Summary VIVUS to Present at Upcoming Conferences
CAMPBELL, Calif. , Aug. 28, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos , Chief Executive Officer at VIVUS , will present at the following conferences: RHK Capital 4th Annual Disruptive Growth Conference hosted by
View HTML
Toggle Summary VIVUS to Share Qsymia® Safety and Efficacy Data with a Global Audience at ICOMES & AOCO 2019
-Conference in Seoul provides opportunity to introduce an international audience to the clinical safety and benefits of Qsymia following its approval in the Republic of Korea - CAMPBELL, Calif. , Aug. 27, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”) today announced that
View HTML
Toggle Summary New Pilot Clinical Study Results Demonstrate that Addition of VIVUS’ Qsymia® to Gastric Sleeve Surgery Significantly Improves Weight Loss Compared with Surgery Alone
-Data published in Surgery for Obesity and Related Diseases also show that patients in the Qsymia group lost more than twice as much weight during preoperative treatment compared with control group- CAMPBELL, Calif. , Aug. 20, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc.
View HTML
Toggle Summary VIVUS Reports Second Quarter 2019 Financial Results
Company to host conference call today at 4:30pm ET CAMPBELL, Calif. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- VIVUS , Inc. (NASDAQ: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with
View HTML